February 14, 2026 07:36 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Rs 5,000 to women ahead of Tamil Nadu polls! Vijay slams Stalin, says: ‘take the money, blow the whistle’ | Modi congratulates Tarique Rahman as BNP clinches majority in Bangladesh polls | Bangladesh Polls: Tarique Rahman-led BNP secures 'absolute majority' with 151 seats in historic comeback | BJP MP files notice to cancel Rahul Gandhi's Lok Sabha membership, seeks life-long ban | Arrested in the morning, out by evening: Tycoon’s son walks free in Lamborghini crash case | ‘Why should you denigrate a section of society?’: Supreme Court pulls up ‘Ghooskhor Pandat’ makers | Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns
AstraZeneca
Pixabay

AstraZeneca's COVID-19 vaccine trial to resume in US

| @indiablooms | Oct 24, 2020, at 03:28 pm

Washington/Xinhua: Multinational pharmaceutical company AstraZeneca said on Friday it will resume the trial of its experimental COVID-19 vaccine in the United States, which has been paused since September.

The company said the U.S. Food and Drug Administration (FDA) authorized the restart of the trial in the United States on Friday, following the resumption of trials in other countries in recent weeks.

The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial, said the company in a statement.

As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on Sept. 6 to allow the examination of safety data by independent monitoring committees, according to the company.

The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume, said the statement.

AstraZeneca said results from the late-stage trials are expected later this year.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.